TRMT5

Across TCGA pan-cancer cohorts, TRMT5 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TRMT5’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TRMT5 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TRMT5 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

HNSC, COAD, and LUAD are the cancer types where TRMT5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRMT5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.464	<.001	11	view →
COAD	Male	III,IV	+0.605	<.001	10	view →
LUAD	Female	II,III,IV	+0.646	<.001	9	view →
CCRCC	Male	II,III,IV	−0.202	<.001	9	view →
LSCC	Male	II,III,IV	+0.790	<.001	8	view →
PDAC	Male	All	+0.267	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TRMT5–HNSC

Open the HNSC breakdown →